Previous 10 | Next 10 |
Adaptimmune Therapeutics ( NASDAQ: ADAP ) stock rose ~17% on Tuesday after Guggenheim upgraded the U.K.-based company's stock to Buy from Neutral. The SA Quant Rating on the shares is Buy , which takes into account factors such as Momentum, Profitability, and Valuation am...
- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint with an overall response rate of ~39% after a single dose of afami-cel - - Adaptimmune plans t...
Summary ADAP has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline. I will continue watching the stock with interest. Just not going to buy now. Adaptimmune ( ADAP ), I noted previously, had been a ...
- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel - - Overall response rate in synovial sarcoma of 39% by independent review -consistent with previous data - -Media...
Penny Stocks To Buy According To 5 Wall Street Analysts Contrary to popular opinion, penny stocks aren’t just lottery tickets or no-name companies. This year, more than others, this has become a fact, especially considering the massive sell-off in the broader markets. Househo...
Mizuho has upgraded Adaptimmune Therapeutics ( NASDAQ: ADAP ) to buy from neutral saying there is now clarity on the regulatory strategy for TCR T-cell therapy afami-cel for solid tumors. The firm kept its price target at $9 (~333% upside based on Tuesday's close...
Shares of the anti-cancer cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having an unusually strong showing today. Specifically, the biotech's stock is up by a whopping 26.8% on sky-high volume as of 2:17 p.m. ET on Tuesday. What's fueling this double-digit ral...
Adaptimmune Therapeutics plc (ADAP) Q3 2022 Earnings Conference Call November 8, 2022 8:00 A.M. ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Elliot Norry - Chief Medical Officer Gavin Wood - Chief Fi...
Adaptimmune press release ( NASDAQ: ADAP ): Q3 GAAP EPS of -$0.04 beats by $0.22 . Revenue of $7M (+483.3% Y/Y) beats by $2.03M . The Company is deprioritizing non-core programs and is also undertaking a restructuring of the Company including a headcount reduct...
Adaptimmune Therapeutics ( NASDAQ: ADAP ) reported updated data from a phase 1 trial called SURPASS evaluating ADP-A2M4CD8 across multiple solid tumor indications. The company said objective response rate (ORR) increased to 52% (from 44% reported at ESMO...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...